patent/EC-SP21044843-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EC-SP21044843-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a73cee5001ad08339ae751c10d9abf71
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
filingDate	2021-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ae105837e8190722d132f95ab140bd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_138058beece131c9f9381c7d694a3c26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b132d36eb2519e6fc743d9f1059fbae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b47be825e111c71394a2c620b4dbffe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9c4f2c5129515a72d935373151fd98c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5aa9adb79b91cc60a0082ed1f17b426
publicationDate	2021-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	EC-SP21044843-A
titleOfInvention	IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS ACTIVIN RECEPTOR KINASE-2 INHIBITORS
abstract	Compounds of Formula (I), methods of using the compounds to inhibit ALK2 activity, and pharmaceutical compositions comprising such compounds are described. The compounds are useful for treating, preventing, or ameliorating diseases or disorders associated with ALK2 activity, such as cancer.
priorityDate	2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411299174 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11029819

Total number of triples: 30.